Malignant Neoplasm of Breast Clinical Trial
Official title:
A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
A Phase Ib Study of Lapatinib in Combination with Caelyx in Patients with Advanced HER2
positive pretreated Breast Cancer.
Treatment Plan:
Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is
administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is
defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib
1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30
mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die. Three
patients will be initially enrolled in each dose level starting from level 1. If none of the
first triplet of patients will develop DLT, the dose will be escalated to the next level for
the subsequent three patients. If one of the first triplets of patients will develop
first-course DLT, a maximum of 3 additional patients will be entered at the same dose level.
The MTD is defined as the dose below that at which two patients have experienced DLT.
Lapatinib will be self-administered by the patient in an outpatient setting at the dose of
the assigned step. Patients will take the drug daily by mouth on days 1 to 21 of each cycle.
Caelyx will be administered by intravenous infusion over an exact period of 1 hour
(preferably by a pump to guarantee a constant speed of infusion) on day
1 of each cycle repeated every 21 days.
STATISTICAL METHODOLOGY:
Evaluation of toxicity: all patients will be evaluable for toxicity from the time of their
first treatment with Caelyx and Lapatinib.
Evaluation of response: all patients included in the study must be assessed for response to
treatment, even if there are major protocol treatment deviations or if they are ineligible.
All conclusions should be based on all eligible patients. Subanalyses may then be performed
on the basis of a subset of patients, excluding those for whom major protocol deviations
have been identified .However, these subanalyses may not serve as the basis for drawing
conclusions concerning treatment efficacy, and the reasons for excluding patients from the
analysis should be clearly reported. The 95% confidence intervals should also be provided.
Title: A Phase Ib Study of Lapatinib in Combination with Caelyx in Patients with Advanced
HER2 positive pretreated Breast Cancer. Protocol Code: IRST 174.01 Phase: Ib Study Design:
open-label,single arm study in patients with advanced HER2 positive breast cancer.
Treatment Plan:
Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is
administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is
defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib
1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30
mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die. Three
patients will be initially enrolled in each dose level starting from level 1. If none of the
first triplet of patients will develop DLT, the dose will be escalated to the next level for
the subsequent three patients. If one of the first triplets of patients will develop
first-course DLT, a maximum of 3 additional patients will be entered at the same dose level.
The MTD is defined as the dose below that at which two patients have experienced DLT.
Lapatinib will be self-administered by the patient in an outpatient setting at the dose of
the assigned step. Patients will take the drug daily by mouth on days 1 to 21 of each cycle.
Caelyx will be administered by intravenous infusion over an exact period of 1 hour
(preferably by a pump to guarantee a constant speed of infusion) on day
1 of each cycle repeated every 21 days.
Objectives:
Primary: to define the MTD and the safety profile of Lapatinib (Tyverb) plus Caelyx.
Secondary: to preliminarily explore the anti tumour activity, to determine the objective
tumor response rate using RECIST criteria.
Sample Size:
No formal sample size estimation is performed as this is primarily a descriptive phase I
trial of safety and tolerability.
STATISTICAL METHODOLOGY:
Evaluation of toxicity: all patients will be evaluable for toxicity from the time of their
first treatment with Caelyx and Lapatinib. Evaluation of response: all patients included in
the study must be assessed for response to treatment, even if there are major protocol
treatment deviations or if they are ineligible. Each patient will be assigned one of the
following categories: 1) complete response, 2) partial response, 3) stable disease, 4)
progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7)
early death because of other cause, or 9) unknown (not assessable, insufficient data). All
of the patients who met the eligibility criteria (with the possible exception of those who
received no study medication) should be included in the main analysis of the response rate.
Patients in response categories 4-9 should be considered as failing to respond to treatment
(PD). Thus, an incorrect treatment schedule or drug administration does not result in
exclusion from the analysis of the response rate.
All conclusions should be based on all eligible patients. Subanalyses may then be performed
on the basis of a subset of patients, excluding those for whom major protocol deviations
have been identified (e.g., early death due to other reasons, early discontinuation of
treatment, major protocol violations, etc.). However, these subanalyses may not serve as the
basis for drawing conclusions concerning treatment efficacy, and the reasons for excluding
patients from the analysis should be clearly reported. The 95% confidence intervals should
also be provided.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02378337 -
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
|
N/A | |
Completed |
NCT01953003 -
Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
|
Phase 3 | |
Not yet recruiting |
NCT01395706 -
ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes
|
Phase 2 | |
Enrolling by invitation |
NCT05486520 -
Low-field MRI for Breast Cancer Screening
|
N/A | |
Completed |
NCT05159778 -
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
|
Phase 2 | |
Active, not recruiting |
NCT03379428 -
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02891681 -
Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment
|
N/A | |
Withdrawn |
NCT03261323 -
Breast Reconstruction Following Breast Cancer in Very High Risk Patients
|
N/A | |
Recruiting |
NCT04669873 -
Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery
|
N/A | |
Completed |
NCT02408393 -
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery
|
Phase 3 | |
Completed |
NCT03289819 -
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC
|
Phase 2 | |
Completed |
NCT02495363 -
Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
|
||
Completed |
NCT03159195 -
Ibrance Real World Insights
|
||
Completed |
NCT03425656 -
Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer
|
Phase 3 | |
Active, not recruiting |
NCT05033756 -
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
|
Phase 2 | |
Not yet recruiting |
NCT01641003 -
Isolation and Characterization of Cancer Stem Cells Using iFP Technique
|
N/A | |
Active, not recruiting |
NCT05364450 -
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03435952 -
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
|
Phase 1 | |
Active, not recruiting |
NCT02204098 -
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
|
Phase 1 | |
Not yet recruiting |
NCT06251544 -
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
|
Phase 1 |